ScreenerHero

GHRS GH Research PLC

NAS · US · Healthcare · Biotechnology · ghres.com
21.06USD-2.14%Mkt Cap: 1.45B $P/E: —

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.45B USD
Enterprise Value1.11B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-48.26M USD
Revenue/Share—
Last Price21.06 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees73
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.63
PEG—
EV/EBITDA-15.63
EV/Revenue—
P/S—
P/B4.11
EPS (TTM)-0.99
EPS (Forward)-1.85
52W Range
12.0446% of range31.44
52W High31.44 USD
52W Low12.04 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-17.25%
ROA-16.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-43.55M USD
CapEx (TTM)121.00K USD
FCF Margin—
FCF Yield-2.53%
Net Debt-362.29M USD
Net Debt/EBITDA5.08
Balance Sheet
Debt/Equity0.00
Current Ratio28.70
Quick Ratio28.21
Book Value/Sh5.24 USD
Cash/Share5.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)42.89 USD
Upside (mean)+103.7%
Target Range38.00 USD – 65.00 USD
38.00+103.7% to mean65.00
# Analysts9
Ownership
Shares Out.68.64M
Float32.37M
Insiders24.46%
Institutions71.44%
Short Interest
Short Ratio15.1d
Short % Float10.04%
Short % Out.3.94%
Shares Short2.70M
Short (prev mo.)3.14M
Technical
SMA 5027.63 (-23.8%)
SMA 20021.01 (+0.2%)
Beta1.32
S&P 52W Chg16.45%
Avg Vol (30d)256.50K
Avg Vol (10d)369.70K
Technical Indicators
RSI (14)25.6
MACD-1.6652
MACD Signal-1.2146
MACD Hist.-0.4506
BB Upper30.25 USD
BB Middle25.28 USD
BB Lower20.32 USD
BB Width39.25%
ATR (14)1.303 USD
Vol Ratio (20d)1.09x